{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T03:54:55Z","timestamp":1762055695497,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Somatostatin receptor ligands (SRLs) represent a true milestone in the medical therapy for acromegaly. The first-generation SRLs (FG-SRLs), octreotide and lanreotide, have demonstrated good efficacy in disease control and tumor shrinkage, and are still considered first-line medical therapies. The development of long-acting release (LAR) formulations has certainly improved the therapeutic tolerability of these drugs, although many patients still experience therapy-related burden. As such, new formulations have recently been developed to improve adherence and therapeutic efficacy and more solutions are on the way. In the case of FG-SRL-resistant disease, pasireotide, the only second generation SRL currently available, demonstrated superiority in disease control and tumor shrinkage compared to FG-SRLs. However, its use in clinical practice is still limited due to concern for impairment in glucose homeostasis. In this review, we discuss the news about the present and future role of SRLs in acromegaly, exploring the therapeutical frontiers of this drug class. Moreover, we provide practical guidance on the use of pasireotide, based on the data in the literature and our clinical experience.<\/jats:p>","DOI":"10.3390\/medicina58060794","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"794","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)"],"prefix":"10.3390","volume":"58","author":[{"given":"Alessandro","family":"Brunetti","sequence":"first","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Antonini","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Saladino","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery (NCH 1), Fondazione IRCCS Istituto Neurologico \u201cCarlo Besta\u201d, 20133 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Lavezzi","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Zampetti","sequence":"additional","affiliation":[{"name":"SC Endocrinologia Grande Ospedale Metropolitano Niguarda Milano, Piazza Ospedale Maggiore 3, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-5589","authenticated-orcid":false,"given":"Renato","family":"Cozzi","sequence":"additional","affiliation":[{"name":"SC Endocrinologia Grande Ospedale Metropolitano Niguarda Milano, Piazza Ospedale Maggiore 3, 20162 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/EJE-07-0358","article-title":"Health-related quality of life in acromegalic subjects: Data from AcroBel, the Belgian Registry on acromegaly","volume":"157","author":"Bex","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12020-017-1458-3","article-title":"Microsurgical therapy of pituitary adenomas","volume":"59","author":"Mortini","year":"2017","journal-title":"Endocrine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.nec.2019.05.009","article-title":"Endocrine Outcomes After Pituitary Surgery","volume":"30","author":"Buttan","year":"2019","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201\u2013995: A very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2015","journal-title":"Pituitary"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Giustina, A., Mazziotti, G., Torri, V., Spinello, M., Floriani, I., and Melmed, S. (2012). Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036411"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study","volume":"99","author":"Colao","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of Hyperglycemia in Patients with Acromegaly Treated with Pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/EJE-19-0732","article-title":"The effect of treatment on quality of life in patients with acromegaly: A prospective study","volume":"182","author":"Wolters","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and Treatment-Related Burden in Patients with Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of Acromegaly Control in Patients Switching from Injectable Somatostatin Receptor Ligands to Oral Octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","first-page":"A520","article-title":"Improved acromegaly patient satisfaction with oral octreotide capsules compared with injectable somatostatin receptor ligands in the MPOWERED trial","volume":"73","author":"Gordon","year":"2021","journal-title":"Endocr. Abstr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: A phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: A phase 2, multicenter study","volume":"83","author":"Pavel","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/17512433.2021.1986004","article-title":"Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly","volume":"14","author":"Neggers","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: Long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fendo.2021.633944","article-title":"The Effect of 6 Months\u2019 Treatment with Pasireotide LAR on Glucose Metabolism in Patients with Resistant Acromegaly in Real-World Clinical Settings","volume":"12","author":"Witek","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: A multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs","volume":"105","author":"Chiloiro","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","article-title":"Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly","volume":"21","author":"Chiloiro","year":"2018","journal-title":"Pituitary"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: Clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-15-0478","article-title":"GHRH excess and blockade in X-LAG syndrome","volume":"23","author":"Daly","year":"2015","journal-title":"Endocrine-Related Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: Long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia Associated with Pasireotide: Results from a Mechanistic Study in Healthy Volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: Medical expert recommendations","volume":"17","author":"Colao","year":"2013","journal-title":"Pituitary"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: A randomized, open-label, Phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fleseriu, M., on behalf of the ACCESS Study Investigators, Rusch, E., and Geer, E.B. (2016). Safety and tolerability of pasireotide long-acting release in acromegaly\u2014Results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine, 55, 247\u2013255.","DOI":"10.1007\/s12020-016-1182-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jcph.213","article-title":"Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study","volume":"54","author":"Breitschaft","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40618-020-01343-0","article-title":"Electrophysiological features in acromegaly: Re-thinking the arrhythmic risk?","volume":"44","author":"Parolin","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12020-020-02501-3","article-title":"Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: An observational French ACROSTUDY cohort study","volume":"71","author":"Kuhn","year":"2020","journal-title":"Endocrine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies","volume":"104","author":"Feola","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: A meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"R274","DOI":"10.1530\/EC-20-0433","article-title":"Novel therapies for acromegaly","volume":"9","author":"Maia","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and Safety of Switching to Pasireotide in Patients with Acromegaly Controlled with Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-13-0032","article-title":"Effects of medical therapies for acromegaly on glucose metabolism","volume":"169","author":"Urbani","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2019-00825","article-title":"Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study","volume":"104","author":"Chiloiro","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1530\/EJE-11-0737","article-title":"DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours","volume":"166","author":"Hoffmann","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"MON-464","DOI":"10.1210\/js.2019-MON-464","article-title":"MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans","volume":"3","author":"Komagata","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"MON-477","DOI":"10.1210\/js.2019-MON-477","article-title":"MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey","volume":"3","author":"Tanaka","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of Somatostatin Receptor Ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/6\/794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:42Z","timestamp":1760138922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/6\/794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["medicina58060794"],"URL":"https:\/\/doi.org\/10.3390\/medicina58060794","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}